Galectin Therapeutics (GALT) Accounts Payables (2010 - 2026)

Galectin Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 52.23% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 52.23% YoY), while the FY2025 annual figure was $3.2 million, down 42.63% from the prior year.
• Accounts Payables was $3.1 million for Q1 2026 at Galectin Therapeutics, down from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.5 million in Q1 2025 to a low of $1.9 million in Q1 2022.
• Historically, Accounts Payables has averaged $3.8 million across 5 years, with a median of $3.2 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Accounts Payables jumped 398.95% in 2022, then tumbled 52.23% in 2026.
• A 5-year view of Accounts Payables shows it stood at $3.9 million in 2022, then surged by 65.32% to $6.4 million in 2023, then retreated by 12.05% to $5.7 million in 2024, then sank by 42.63% to $3.2 million in 2025, then declined by 3.82% to $3.1 million in 2026.
• The last three Accounts Payables figures came in at $3.1 million (Q1 2026), $3.2 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.